|
65679638212eaade2e0edcee
|
2018
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
20180C3063
|
1111
|
8
|
Peru
|
South America
|
UMICs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0.988733
|
0.988733
|
0
|
0
|
0.988733
|
0.988733
|
0
|
0.988733
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TO STRENGTHEN THE IMT AVH R-AN...D-D CAPACITIES TO DELIVER STRATEGIES AND/OR TOOLS FOR DIAGNOSIS, SURVEILLANCE AND CONTROL OF INFECTIOUS DISEASES
more
|
To strengthen the IMT AvH R-an...d-D capacities to deliver strategies and/or tools for diagnosis, surveillance and control of infectious diseases
more
|
|
Change!
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679638212eaade2e0edcef
|
2018
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
20180C3061
|
1111
|
8
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
1.16661
|
1.16661
|
0
|
0
|
1.16661
|
1.16661
|
0
|
1.16661
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
STRENGTHENING THE CAPACITY FOR... RESEARCH, TEACHING, POLICY ADVICE, ADVOCACY AND NETWORKING OF THE PARTNERS IN THE FIELD ON HUMAN AND ANIMAL HEALTH
more
|
Strengthening the capacity for... research, teaching, policy advice, advocacy and networking of the partners in the field on human and animal health
more
|
|
Change!
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679638212eaade2e0edcf0
|
2019
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2019CO3058
|
1111
|
8
|
Benin
|
South of Sahara
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0.342091
|
0.342091
|
0
|
0
|
0.342091
|
0.342091
|
0
|
0.342091
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RENFORCEMENT INSTITUTIONNEL DE... LRM POUR DES SERVICES DE QUALITÉ ET L'AMÉLIORATION DES SOINS DE SANTÉ AU NIVEAU NATIONAL ET RÉGIONAL, SUR LES MYCOBACTÉ
more
|
Renforcement institutionnel de... LRM pour des services de qualité et l'amélioration des soins de santé au niveau national et régional, sur les mycobacté
more
|
Background: Building on ongoin...g collaborations, several units of the Institute of Tropical Medicine (ITM) will collaborate with one Beninese partner institution, aiming to increase local capacity for research, and application of its results to improved health management. The project will support direct research activities to increase staff capacities, and the application of results into national- and regional healthcare practice. The promotor, Prof Dr Dissou Affolabi, is based at the Laboratoire de Référence des Mycobactéries (LRM). Besides mycobacterial diagnostic services, training of researchers, and upgrade of LRM to a supra-national reference laboratory, the programme will reinforce Prof Affolabi's work on antibiotic resistance at the Centre National Hospitalier Universitaire (CNHU). Expected laboratory results focus on improved quality, including formal accreditation of LRM and supervision of laboratories in other countries. In addition, the creation of a grant administration office will strengthen the general management of the laboratory research activities, including the quality of the accounting.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679638212eaade2e0edcf1
|
2019
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2019CO3059
|
1111
|
8
|
Burkina Faso
|
South of Sahara
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0.442535
|
0.442535
|
0
|
0
|
0.442535
|
0.442535
|
0
|
0.442535
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RENFORCER LA CAPACITÉ DE RECH...ERCHE LIÉE À LA SANTÉ DANS LE CONTEXTE DES RESSOURCES LIMITÉES DU BURKINA FASO
more
|
Renforcer la capacité de rech...erche liée à la santé dans le contexte des ressources limitées du Burkina Faso
more
|
Background: The new 5-year pro...gram builds on the ongoing collaboration between the Clinical Research Unit of Nanoro (CRUN) and the Institute of Tropical Medicine (ITM). It aims specifically to strengthen the research capacity in the resource limited setting of Nanoro. The program will expand and strengthen CRUN laboratory capacities towards biomedical and molecular studies, including parasite and bacterial genotyping and biomarker studies. Given the changing epidemiological context CRUN intends to extend its portfolio to diagnostics and epidemiology of invasive bacterial diseases and sexual and reproductive health (SRH) in a health context. The collaboration with hospitals and public health institutes will be strengthened to build capacity for management of bacterial diseases and conduct interventions in the fields of antibiotic stewardship, infection control, clinical trials behavioral studies. In order to evaluate disease burdens and incidence for directing public health interventions, the Health and Demographic Surveillance System will be exploited to monitor the impact of malaria control measures, to address the etiological spectrum of non-malaria febrile illnesses and to study the socio-cultural factors of human health behavior. Interventions can only be successful and sustainable when the human capital is strengthened. Therefore the program will focus on exchange between CRUN, Centre Muraz and ITM staff, provide trainings and support doctoral and master of science candidates, taking into account the gender balance.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679638212eaade2e0edcf2
|
2019
|
Belgium
|
Flanders Official Regional Min...istries
more
|
2019CO3334
|
1759
|
8
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0.94705
|
0.94705
|
0
|
0
|
0.94705
|
0.94705
|
0
|
0.94705
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUPPORT TO THE OUTBREAK RESEAR...CH TEAM (INSTITUTE OF TROPICAL MEDICINE ANTWERP)
more
|
Support to the Outbreak Resear...ch Team (Institute of Tropical Medicine Antwerp)
more
|
Background: This interdiscplin...ary team will be dedicated to scientific research in the field of emergency outbreaks of infectious diseases.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679638212eaade2e0edcf3
|
2019
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2019CO3060
|
1111
|
8
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0.437188
|
0.437188
|
0
|
0
|
0.437188
|
0.437188
|
0
|
0.437188
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TO ENHANCE THE RESEARCH CAPACI...TY AND EVIDENCE BASED MEDICAL PRACTICE IN TROPICAL AND POVERTY RELATED DISEASES IN ETHIOPIA
more
|
To enhance the research capaci...ty and evidence based medical practice in tropical and poverty related diseases in Ethiopia
more
|
Background: The start-up Frame...work Agreement 3-III (FA3-III) project (2014-2016) with Gondar College of Medical and Health Sciences (GCMHS), at the University of Gondar (UoG) was geared towards capacity building on clinical research and training. There was a strong focus on clinical medicine and laboratory quality, with visceral leishmaniasis – a fatal parasitic neglected disease – as main focus. Building on the needs jointly identified during FA3-III, in the present proposal, we aim to consolidate the visceral leishmaniasis research, broaden research activities towards other neglected tropical diseases/poverty related diseases including cutaneous leishmaniasis and tuberculosis, consolidate lab quality (Good Clinical and Laboratory Practice, GCLP) and capacity for sample storage (biobanking), establish the required laboratory (molecular, immunology) platforms to support the clinical and laboratory research activities on the various topics, and introduce a strong component of antibiotic stewardship and surveillance of antibiotic resistance, backed up by a quality microbiology laboratory. All these activities will be complemented with linked training activities, in particular on research methodology, good clinical practice, clinical decision making and evidence-based medicine. In depth training in laboratory skills and laboratory quality will be organized as well. From a small project (FA3-III) involving a small number of clinical units, the project (Framework Agreement 4, FA4) has matured towards a comprehensive project covering biomedical, clinical and public health sciences and involving a high number of units at the Institute of Tropical Medicine (ITM) and their UoG counterparts. Our ambition is that FA4 will lead to strong, independent Ethiopian researchers and trainers, contributing to enhancing the evidence base of health related interventions, and serving as an inspiration for their students and (younger) colleagues.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679639212eaade2e0edcf4
|
2019
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2019CO3063
|
1111
|
8
|
Peru
|
South America
|
UMICs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0.728988
|
0.728988
|
0
|
0
|
0.728988
|
0.728988
|
0
|
0.728988
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TO STRENGTHEN THE IMT AVH R-AN...D-D CAPACITIES TO DELIVER STRATEGIES AND/OR TOOLS FOR DIAGNOSIS, SURVEILLANCE AND CONTROL OF INFECTIOUS DISEASES
more
|
To strengthen the IMT AvH R-an...d-D capacities to deliver strategies and/or tools for diagnosis, surveillance and control of infectious diseases
more
|
Background: The Institute of T...ropical Medicine Alexander von Humboldt has a longstanding relationship with the Institute of Tropical Medicine of Antwerp in the frame of fundamental and translational research for improving health. We have developed over the years a strong partnership in the area of infectious diseases that pose significant public health concerns in Peru and the Latin American region (and globally as well): leishmaniasis, malaria, tuberculosis (TB), human T-lymphotropic virus-1 (HTLV-1) associated diseases, and bacterial diseases. Current proposal builds further on the acquired knowledge and experience, and includes an additional component on arboviral infections. Through scientific collaboration, we believe we can have a positive effect on treatment and prevention of the mentioned conditions, by acting at various levels. While the leishmaniasis, HTLV-1, and arbovirus components focus on development of field-applicable diagnostic assays, malaria is developing a point-of-care (POC) diagnostic tool for vulnerable populations and molecular tools for surveillance (in view of malaria elimination), and TB research is directed on surveillance and prevention. Further, we can positively impact treatment of bacterial diseases by monitoring of resistance against antimicrobial agents. In all these domains, we will work in settings relevant for the patients or populations at risk. Further, we will strengthen local human capacity in the institute by supporting doctoral and postdoctoral researchers.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679639212eaade2e0edcf5
|
2019
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2019CO3061
|
1111
|
8
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
1.06814
|
1.06814
|
0
|
0
|
1.06814
|
1.06814
|
0
|
1.06814
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
STRENGTHENING THE CAPACITY FOR... RESEARCH, TEACHING, POLICY ADVICE, ADVOCACY AND NETWORKING OF THE PARTNERS IN THE FIELD ON HUMAN AND ANIMAL HEALTH
more
|
Strengthening the capacity for... research, teaching, policy advice, advocacy and networking of the partners in the field on human and animal health
more
|
Background: Research and educa...tion to improve animal and human health and welfare in Southern Africa Drawing on their position as South African Higher Education Institutions with capacity to support the African Region more generally, the Department of Veterinary Tropical Diseases (UP) and the School of Public Health (UWC) will partner with the Institute of Tropical Medicine to strengthen the capacity to respond to key human and veterinary health challenges in the Region. This will done by: 1) Building an evidence base through collaborative research on zoonotic and animal diseases (DVTD) and health policy and systems (SOPH), that takes into account the specific ecological and socio-economic context, in South Africa and the Region; 2) Collaborating in post graduate research training (masters, doctoral and post doctoral) on these themes to candidates from South Africa and the Region; 3) Enhancing south-south and north-south dialogue and networks of teaching and research collaboration; 4) Engaging with local communities, practitioners and policy makers to address human and veterinary health challenges in South Africa and the Region. For the ITM, Higher Education Institutions and their staff and students are the main beneficiaries. These are reached through capacity development activities for researchers and research centres, co-production of research and of educational programmes, and networking.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679639212eaade2e0edcf6
|
2020
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2020CO3058
|
1111
|
8
|
Benin
|
South of Sahara
|
LDCs
|
ODA Grants
|
7
|
10
|
110
|
B01
|
0.40919
|
0.40919
|
0
|
0
|
0.40919
|
0.40919
|
|
0.40919
|
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RENFORCEMENT INSTITUTIONNEL DE... LRM POUR DES SERVICES DE QUALITÉ ET L'AMÉLIORATION DES SOINS DE SANTÉ AU NIVEAU NATIONAL ET RÉGIONAL, SUR LES MYCOBACTÉ
more
|
Renforcement institutionnel de... LRM pour des services de qualité et l'amélioration des soins de santé au niveau national et régional, sur les mycobacté
more
|
Background: Building on ongoin...g collaborations, several units of the Institute of Tropical Medicine (ITM) will collaborate with one Beninese partner institution, aiming to increase local capacity for research, and application of its results to improved health management. The project will support direct research activities to increase staff capacities, and the application of results into national- and regional healthcare practice. The promotor, Prof Dr Dissou Affolabi, is based at the Laboratoire de Référence des Mycobactéries (LRM). Besides mycobacterial diagnostic services, training of researchers, and upgrade of LRM to a supra-national reference laboratory, the programme will reinforce Prof Affolabi's work on antibiotic resistance at the Centre National Hospitalier Universitaire (CNHU). Expected laboratory results focus on improved quality, including formal accreditation of LRM and supervision of laboratories in other countries. In addition, the creation of a grant administration office will strengthen the general management of the laboratory research activities, including the quality of the accounting.
more
|
0
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679639212eaade2e0edcf7
|
2020
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2020CO3059
|
1111
|
8
|
Burkina Faso
|
South of Sahara
|
LDCs
|
ODA Grants
|
7
|
10
|
110
|
B01
|
0.587629
|
0.587629
|
0
|
0
|
0.587629
|
0.587629
|
|
0.587629
|
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RENFORCER LA CAPACITÉ DE RECH...ERCHE LIÉE À LA SANTÉ DANS LE CONTEXTE DES RESSOURCES LIMITÉES DU BURKINA FASO
more
|
Renforcer la capacité de rech...erche liée à la santé dans le contexte des ressources limitées du Burkina Faso
more
|
Background: The new 5-year pro...gram builds on the ongoing collaboration between the Clinical Research Unit of Nanoro (CRUN) and the Institute of Tropical Medicine (ITM). It aims specifically to strengthen the research capacity in the resource limited setting of Nanoro. The program will expand and strengthen CRUN laboratory capacities towards biomedical and molecular studies, including parasite and bacterial genotyping and biomarker studies. Given the changing epidemiological context CRUN intends to extend its portfolio to diagnostics and epidemiology of invasive bacterial diseases and sexual and reproductive health (SRH) in a health context. The collaboration with hospitals and public health institutes will be strengthened to build capacity for management of bacterial diseases and conduct interventions in the fields of antibiotic stewardship, infection control, clinical trials behavioral studies. In order to evaluate disease burdens and incidence for directing public health interventions, the Health and Demographic Surveillance System will be exploited to monitor the impact of malaria control measures, to address the etiological spectrum of non-malaria febrile illnesses and to study the socio-cultural factors of human health behavior. Interventions can only be successful and sustainable when the human capital is strengthened. Therefore the program will focus on exchange between CRUN, Centre Muraz and ITM staff, provide trainings and support doctoral and master of science candidates, taking into account the gender balance.
more
|
0
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679639212eaade2e0edcf8
|
2020
|
Belgium
|
Flanders Official Regional Min...istries
more
|
2020CO6564
|
3822
|
8
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D01
|
1.025641
|
1.025641
|
0
|
0
|
1.025641
|
1.025641
|
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUPPORT FOR THE CONSTRUCTION O...F AN INSECTARIUM
more
|
Support for the construction o...f an insectarium
more
|
Background: The insectarium wi...ll ensure that tropical diseases including those linked to climate change can be investigated even better.The new insectarium houses a wide range of insects such as tiger mosquitoes, malaria mosquitoes, tsetse flies and sand flies. These insects can transmit infections such as zika, dengue, chikungunya, malaria, sleeping sickness, leishmania, among others. The interactions between pathogen, insect and the environment is still heavily underexplored. The new insectarium gives ITM scientists the opportunity to close this gap and gain new insights into infectious diseases. With this research area, ITM will be one of the few institutions in Europe where this range of insects is studied.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679639212eaade2e0edcf9
|
2020
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2020CO3060
|
1111
|
8
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
7
|
10
|
110
|
B01
|
0.523868
|
0.523868
|
0
|
0
|
0.523868
|
0.523868
|
|
0.523868
|
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TO ENHANCE THE RESEARCH CAPACI...TY AND EVIDENCE BASED MEDICAL PRACTICE IN TROPICAL AND POVERTY RELATED DISEASES IN ETHIOPIA
more
|
To enhance the research capaci...ty and evidence based medical practice in tropical and poverty related diseases in Ethiopia
more
|
Background: The start-up Frame...work Agreement 3-III (FA3-III) project (2014-2016) with Gondar College of Medical and Health Sciences (GCMHS), at the University of Gondar (UoG) was geared towards capacity building on clinical research and training. There was a strong focus on clinical medicine and laboratory quality, with visceral leishmaniasis – a fatal parasitic neglected disease – as main focus. Building on the needs jointly identified during FA3-III, in the present proposal, we aim to consolidate the visceral leishmaniasis research, broaden research activities towards other neglected tropical diseases/poverty related diseases including cutaneous leishmaniasis and tuberculosis, consolidate lab quality (Good Clinical and Laboratory Practice, GCLP) and capacity for sample storage (biobanking), establish the required laboratory (molecular, immunology) platforms to support the clinical and laboratory research activities on the various topics, and introduce a strong component of antibiotic stewardship and surveillance of antibiotic resistance, backed up by a quality microbiology laboratory. All these activities will be complemented with linked training activities, in particular on research methodology, good clinical practice, clinical decision making and evidence-based medicine. In depth training in laboratory skills and laboratory quality will be organized as well. From a small project (FA3-III) involving a small number of clinical units, the project (Framework Agreement 4, FA4) has matured towards a comprehensive project covering biomedical, clinical and public health sciences and involving a high number of units at the Institute of Tropical Medicine (ITM) and their UoG counterparts. Our ambition is that FA4 will lead to strong, independent Ethiopian researchers and trainers, contributing to enhancing the evidence base of health related interventions, and serving as an inspiration for their students and (younger) colleagues.
more
|
0
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
65679639212eaade2e0edcfa
|
2020
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2020CO3063
|
1111
|
8
|
Peru
|
South America
|
UMICs
|
ODA Grants
|
7
|
10
|
110
|
B01
|
0.838641
|
0.838641
|
0
|
0
|
0.838641
|
0.838641
|
|
0.838641
|
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TO STRENGTHEN THE IMT AVH R-AN...D-D CAPACITIES TO DELIVER STRATEGIES AND/OR TOOLS FOR DIAGNOSIS, SURVEILLANCE AND CONTROL OF INFECTIOUS DISEASES
more
|
To strengthen the IMT AvH R-an...d-D capacities to deliver strategies and/or tools for diagnosis, surveillance and control of infectious diseases
more
|
Background: The Institute of T...ropical Medicine Alexander von Humboldt has a longstanding relationship with the Institute of Tropical Medicine of Antwerp in the frame of fundamental and translational research for improving health. We have developed over the years a strong partnership in the area of infectious diseases that pose significant public health concerns in Peru and the Latin American region (and globally as well): leishmaniasis, malaria, tuberculosis (TB), human T-lymphotropic virus-1 (HTLV-1) associated diseases, and bacterial diseases. Current proposal builds further on the acquired knowledge and experience, and includes an additional component on arboviral infections. Through scientific collaboration, we believe we can have a positive effect on treatment and prevention of the mentioned conditions, by acting at various levels. While the leishmaniasis, HTLV-1, and arbovirus components focus on development of field-applicable diagnostic assays, malaria is developing a point-of-care (POC) diagnostic tool for vulnerable populations and molecular tools for surveillance (in view of malaria elimination), and TB research is directed on surveillance and prevention. Further, we can positively impact treatment of bacterial diseases by monitoring of resistance against antimicrobial agents. In all these domains, we will work in settings relevant for the patients or populations at risk. Further, we will strengthen local human capacity in the institute by supporting doctoral and postdoctoral researchers.
more
|
0
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
6567963a212eaade2e0edcfb
|
2020
|
Belgium
|
Directorate General for Co-ope...ration and Development
more
|
2020CO3061
|
1111
|
8
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
7
|
10
|
110
|
B01
|
1.419204
|
1.419204
|
0
|
0
|
1.419204
|
1.419204
|
|
1.419204
|
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
STRENGTHENING THE CAPACITY FOR... RESEARCH, TEACHING, POLICY ADVICE, ADVOCACY AND NETWORKING OF THE PARTNERS IN THE FIELD ON HUMAN AND ANIMAL HEALTH
more
|
Strengthening the capacity for... research, teaching, policy advice, advocacy and networking of the partners in the field on human and animal health
more
|
Background: Research and educa...tion to improve animal and human health and welfare in Southern Africa Drawing on their position as South African Higher Education Institutions with capacity to support the African Region more generally, the Department of Veterinary Tropical Diseases (UP) and the School of Public Health (UWC) will partner with the Institute of Tropical Medicine to strengthen the capacity to respond to key human and veterinary health challenges in the Region. This will done by: 1) Building an evidence base through collaborative research on zoonotic and animal diseases (DVTD) and health policy and systems (SOPH), that takes into account the specific ecological and socio-economic context, in South Africa and the Region, 2) Collaborating in post graduate research training (masters, doctoral and post doctoral) on these themes to candidates from South Africa and the Region, 3) Enhancing south-south and north-south dialogue and networks of teaching and research collaboration, 4) Engaging with local communities, practitioners and policy makers to address human and veterinary health challenges in South Africa and the Region. For the ITM, Higher Education Institutions and their staff and students are the main beneficiaries. These are reached through capacity development activities for researchers and research centres, co-production of research and of educational programmes, and networking.
more
|
0
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
ITM Institute of Tropical Medi...cine ANTWERPEN - ANVERS
more
|
|
|
|
6567963a212eaade2e0edcfc
|
2015
|
Canada
|
GAC
|
20152001710001
|
D001647001
|
1
|
Guinea
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.87749
|
1.87749
|
0
|
0
|
1.87749
|
1.87749
|
0
|
1.87749
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUPPORT TO CLINICAL TRIALS FOR... EBOLA VACCINE / APPUI AUX ESSAIS CLINIQUES POUR UN VACCIN CONTRE LE VIRUS EBOLA
more
|
Support to Clinical Trials for... Ebola Vaccine / Appui aux essais cliniques pour un vaccin contre le virus Ebola
more
|
The project aims to support Ca...nadian activities towards phase 2/3 clinical trials in Africa. These trials accelerate safety and efficacy testing and use of vaccine candidate(s) among at-risk populations such as front-line health-care workers and first-responders in Africa. The results inform the approval of vaccine candidates for future use to prevent Ebola transmission. Activities led by the research teams include: (1) coordinating in-field preparations to facilitate the clinical trial, including: national approvals, capacity building of Africa organizations involved in the clinical trial, recruitment of field personnel and clinical trials participants; (2) planning, oversight and execution of the clinical trial; and (3) analyzing and reporting of results. This project is coordinated by International Development Research Centre (IDRC), in partnership with Canadian Institutes of Health Research (CIHR), Public Health Agency of Canada (PHAC) and Department of Foreign Affairs, Trade and Development Canada (DFATD). Partnerships are being built between Canadian researchers with African institutions and researchers in the implementation of this project to help build the capacity of African researchers and institutions to conduct high-level biomedical research like clinical trials and facilitate future collaboration. In addition, the project improves knowledge sharing on Ebola and similar health emergencies among African governments and research organizations to enable them to effectively respond to future outbreaks. / Ce projet vise à soutenir les activités que mène le Canada liées aux essais cliniques des phases 2 et 3 en Afrique. Ces derniers ont pour but d'accélérer la vérification de l'innocuité et de l'efficacité des vaccins expérimentaux ainsi que leur utilisation chez les populations à risque, comme les travailleurs de la santé de première ligne et les premiers répondants en Afrique. L'approbation des vaccins expérimentaux en vue d'une utilisation future pour prévenir la transmission du virus Ebola sera accordée en fonction des résultats des essais cliniques. Parmi les activités menées par les équipes de recherche : 1) la coordination des préparatifs sur le terrain afin de faciliter les essais cliniques, y compris les approbations nationales, le renforcement des capacités des organisations africaines participant aux essais cliniques, le recrutement du personnel sur le terrain et des participants aux essais cliniques; 2) la planification, la surveillance et la réalisation des essais cliniques; 3) l'analyse des résultats et l'établissement de rapports sur ceux ci. Ce projet est coordonné par le Centre de recherches pour le développement international, en partenariat avec les Instituts de recherche en santé du Canada, l'Agence de la santé publique du Canada et Affaires étrangères, Commerce et Développement Canada. Des chercheurs canadiens ainsi que des établissements et des chercheurs africains établissent actuellement des partenariats dans
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
International Development Rese...arch Centre
more
|
|
|
|
6567963a212eaade2e0edcfd
|
2015
|
Canada
|
GAC
|
20152001710003
|
D001647001
|
1
|
Liberia
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.234687
|
0.234687
|
0
|
0
|
0.234687
|
0.234687
|
0
|
0.234687
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUPPORT TO CLINICAL TRIALS FOR... EBOLA VACCINE / APPUI AUX ESSAIS CLINIQUES POUR UN VACCIN CONTRE LE VIRUS EBOLA
more
|
Support to Clinical Trials for... Ebola Vaccine / Appui aux essais cliniques pour un vaccin contre le virus Ebola
more
|
The project aims to support Ca...nadian activities towards phase 2/3 clinical trials in Africa. These trials accelerate safety and efficacy testing and use of vaccine candidate(s) among at-risk populations such as front-line health-care workers and first-responders in Africa. The results inform the approval of vaccine candidates for future use to prevent Ebola transmission. Activities led by the research teams include: (1) coordinating in-field preparations to facilitate the clinical trial, including: national approvals, capacity building of Africa organizations involved in the clinical trial, recruitment of field personnel and clinical trials participants; (2) planning, oversight and execution of the clinical trial; and (3) analyzing and reporting of results. This project is coordinated by International Development Research Centre (IDRC), in partnership with Canadian Institutes of Health Research (CIHR), Public Health Agency of Canada (PHAC) and Department of Foreign Affairs, Trade and Development Canada (DFATD). Partnerships are being built between Canadian researchers with African institutions and researchers in the implementation of this project to help build the capacity of African researchers and institutions to conduct high-level biomedical research like clinical trials and facilitate future collaboration. In addition, the project improves knowledge sharing on Ebola and similar health emergencies among African governments and research organizations to enable them to effectively respond to future outbreaks. / Ce projet vise à soutenir les activités que mène le Canada liées aux essais cliniques des phases 2 et 3 en Afrique. Ces derniers ont pour but d'accélérer la vérification de l'innocuité et de l'efficacité des vaccins expérimentaux ainsi que leur utilisation chez les populations à risque, comme les travailleurs de la santé de première ligne et les premiers répondants en Afrique. L'approbation des vaccins expérimentaux en vue d'une utilisation future pour prévenir la transmission du virus Ebola sera accordée en fonction des résultats des essais cliniques. Parmi les activités menées par les équipes de recherche : 1) la coordination des préparatifs sur le terrain afin de faciliter les essais cliniques, y compris les approbations nationales, le renforcement des capacités des organisations africaines participant aux essais cliniques, le recrutement du personnel sur le terrain et des participants aux essais cliniques; 2) la planification, la surveillance et la réalisation des essais cliniques; 3) l'analyse des résultats et l'établissement de rapports sur ceux ci. Ce projet est coordonné par le Centre de recherches pour le développement international, en partenariat avec les Instituts de recherche en santé du Canada, l'Agence de la santé publique du Canada et Affaires étrangères, Commerce et Développement Canada. Des chercheurs canadiens ainsi que des établissements et des chercheurs africains établissent actuellement des partenariats dans
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
International Development Rese...arch Centre
more
|
|
|
|
6567963a212eaade2e0edcfe
|
2015
|
Canada
|
GAC
|
20152001710002
|
D001647001
|
1
|
Sierra Leone
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.234687
|
0.234687
|
0
|
0
|
0.234687
|
0.234687
|
0
|
0.234687
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUPPORT TO CLINICAL TRIALS FOR... EBOLA VACCINE / APPUI AUX ESSAIS CLINIQUES POUR UN VACCIN CONTRE LE VIRUS EBOLA
more
|
Support to Clinical Trials for... Ebola Vaccine / Appui aux essais cliniques pour un vaccin contre le virus Ebola
more
|
The project aims to support Ca...nadian activities towards phase 2/3 clinical trials in Africa. These trials accelerate safety and efficacy testing and use of vaccine candidate(s) among at-risk populations such as front-line health-care workers and first-responders in Africa. The results inform the approval of vaccine candidates for future use to prevent Ebola transmission. Activities led by the research teams include: (1) coordinating in-field preparations to facilitate the clinical trial, including: national approvals, capacity building of Africa organizations involved in the clinical trial, recruitment of field personnel and clinical trials participants; (2) planning, oversight and execution of the clinical trial; and (3) analyzing and reporting of results. This project is coordinated by International Development Research Centre (IDRC), in partnership with Canadian Institutes of Health Research (CIHR), Public Health Agency of Canada (PHAC) and Department of Foreign Affairs, Trade and Development Canada (DFATD). Partnerships are being built between Canadian researchers with African institutions and researchers in the implementation of this project to help build the capacity of African researchers and institutions to conduct high-level biomedical research like clinical trials and facilitate future collaboration. In addition, the project improves knowledge sharing on Ebola and similar health emergencies among African governments and research organizations to enable them to effectively respond to future outbreaks. / Ce projet vise à soutenir les activités que mène le Canada liées aux essais cliniques des phases 2 et 3 en Afrique. Ces derniers ont pour but d'accélérer la vérification de l'innocuité et de l'efficacité des vaccins expérimentaux ainsi que leur utilisation chez les populations à risque, comme les travailleurs de la santé de première ligne et les premiers répondants en Afrique. L'approbation des vaccins expérimentaux en vue d'une utilisation future pour prévenir la transmission du virus Ebola sera accordée en fonction des résultats des essais cliniques. Parmi les activités menées par les équipes de recherche : 1) la coordination des préparatifs sur le terrain afin de faciliter les essais cliniques, y compris les approbations nationales, le renforcement des capacités des organisations africaines participant aux essais cliniques, le recrutement du personnel sur le terrain et des participants aux essais cliniques; 2) la planification, la surveillance et la réalisation des essais cliniques; 3) l'analyse des résultats et l'établissement de rapports sur ceux ci. Ce projet est coordonné par le Centre de recherches pour le développement international, en partenariat avec les Instituts de recherche en santé du Canada, l'Agence de la santé publique du Canada et Affaires étrangères, Commerce et Développement Canada. Des chercheurs canadiens ainsi que des établissements et des chercheurs africains établissent actuellement des partenariats dans
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
International Development Rese...arch Centre
more
|
|
|
|
6567963a212eaade2e0edcff
|
2015
|
Canada
|
IDRC
|
2009005509XAB0
|
105509
|
3
|
Africa, regional
|
Africa
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.000977861
|
0.00216694
|
0
|
0
|
0.000977861
|
0.00216694
|
0
|
0.000977861
|
0
|
0
|
Communicable diseases
|
Communicable diseases Other
|
100
|
ECOHEALTH EMERGING INFECTIOUS ...DISEASES RESEARCH INITIATIVE (ECOEID)
more
|
Ecohealth Emerging Infectious ...Diseases Research Initiative (EcoEID)
more
|
New infectious diseases, mostl...y of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi-country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
International Development Rese...arch Centre
more
|
|
|
|
6567963a212eaade2e0edd00
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2016008404XZA1
|
108404
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.128568
|
0
|
0
|
0
|
0.128568
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EPITOPE FOCUSED IMMUNOGENS AND... RECOMBINANT ANTIBODY THERAPEUTICS FOR THE CONTROL OF TROPICAL DISEASES
more
|
Epitope focused immunogens and... recombinant antibody therapeutics for the control of tropical diseases
more
|
Tropical diseases in humans an...d livestock can cause death and remain a huge economic and social burden in developing countries. Currently, 3.6 billion people are at risk of dengue infection. Endemic in 100 countries, with an estimated 390 million annual infections and approximately 500,000 hospitalizations yearly, dengue fever is a worldwide challenge for public health officials and policymakers. East Coast fever is a tick-borne disease affecting cattle, caused by the protozoan parasite Theileria parva. With a 3–4 week incubation period and 100% mortality rate in exotic cattle, it has a devastating economic impact on pastoralists and smallholder farmers in Africa. Combining cutting-edge immunology and protein engineering methods, this collaborative research project aims to develop affordable antibody-based therapies for dengue patients and improved vaccines for the control of dengue fever and East Coast fever in both humans and animals. The core technologies that will be employed reduce the use of animals in research and are easy and affordable to implement, which make these approaches particularly appealing to research groups based in low- and middle-income countries. In Canada, the project is led by the University of Toronto, in collaboration with Tel Aviv University (Israel), the International Livestock Research Institute (Kenya), the SciGenom Labs (India), and the Albert Einstein College of Medicine (USA). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, a partnership between IDRC, the Canadian Institutes for Health Research, the Israel Science Foundation, and the Azrieli Foundation. This seven-year, CA$35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. Projects include a plan for integrating researchers from low- and middle-income countries to establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governing Council of the U...niversity of Toronto
more
|
|
|
|
6567963a212eaade2e0edd01
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2016008406XZA1
|
108406
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.137113
|
0
|
0
|
0
|
0.137113
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
IMPROVING MICROPHAGE INNATE IM...MUNITY BY MODULATING PROTEIN TYROSINE PHOSPHATASES: THE COMPLETE MOUSE AND HUMAN PTPOMES
more
|
Improving microphage innate im...munity by modulating protein tyrosine phosphatases: The complete mouse and human PTPomes
more
|
Diseases that result from an i...nfection are most often resolved by cells that use an immune response to clear foreign agents. These cells include macrophages, which are the predominant type of cell that eliminates infectious agents in a process called phagocytosis, or eating the foreign particles. There are two specialized subsets of macrophages: pro-inflammatory and anti-inflammatory macrophages. This research focuses on the pro-inflammatory macrophages, also called M1, which are responsible for triggering an immune response against infectious agents to promote their killing.This project investigates the therapeutic potential of inhibiting a class of proteins named protein tyrosine phosphatases (PTPs) to treat infectious diseases. Recent findings suggest that mice in which PTP-RO is inhibited have an increased number of macrophages in the bone marrow, while PTP-1B leads to a pro-inflammatory response in macrophages. The authors hypothesize that certain PTPs favour the generation of the pro-inflammatory M1 macrophages, thereby regulating the functions leading to promoting immune surveillance and killing of infectious agents. The project proposes that regulating the expression and activity of these PTPs may improve the function of these macrophages and promote better anti-pathogenic responses. The research will improve understanding of infectious disease progression and contribute to the development of new methods of treatment for infectious diseases by regulating specific PTPs. The project is led in Canada by McGill University, with the collaboration of the Weizmann Institute (Israel) and the University of Hyderabad (India). This project was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, a partnership between Canada's International Development Research Centre, the Canadian Institutes for Health Research, the Israel Science Foundation, and the Azrieli Foundation. This 7-year, $35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. All projects include a plan for integrating researchers from low- and middle-income countries that will establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Royal Institution for the ...Advancement of Learning/McGill University
more
|
|
|
|
6567963b212eaade2e0edd02
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2016008407XZA1
|
108407
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.119883
|
0
|
0
|
0
|
0.119883
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MITOCHONDRIAL CONTRIBUTION TO ...INNATE IMMUNE PATHWAYS
more
|
Mitochondrial contribution to ...innate immune pathways
more
|
The ability of cells in the bo...dy to recognize bacteria and viruses is critical to survival. Depending on the type of infection, the cell will activate different pathways that generally lead to two distinct responses; first, the cell will secrete proteins called cytokines that alert neighbouring cells to the infection, particularly cells of the immune system. Second, a series of events are triggered to shut down the replication of the pathogen inside the cell. This direct cellular response to infection is called innate immunity. Over the past few years, researchers have identified a critical role for an intracellular organelle, called mitochondria, in the propagation of these signals. Mitochondria are well known as the energy powerhouse of the cell, however, they can also act as a platform to assemble anti-viral and anti-inflammatory signalling. In addition, mitochondria still retain bacterial signatures, including their own unmethylated DNA, as well as the machinery to translate proteins. It was recently shown that this mitochondrial DNA is released into the cell cytoplasm under certain stress conditions. When this happens, the cellular antiviral responses are initiated, as if the cell was infected with bacteria. In this way, mitochondria play a central role as both a signalling platform to launch the protective response to infection, and as a direct activator of this response when their own DNA is released. This project aims to investigate the role of mitochondria in innate immune responses and to develop a detailed understanding of how mitochondria control innate immune signalling pathways. The project is led in Canada by the Montreal Neurological Institute – McGill University in collaboration with the Weizmann Institute (Israel), Universidad Andres Bello (Chile), and the National Institute of Biological Sciences (China). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, which is a partnership between Canada's International Development Research Centre, the Canadian Institutes for Health Research, the Israel Science Foundation and the Azrieli Foundation. This seven-year, $35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. All projects include a plan for integrating researchers from low- and middle-income countries that will establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Royal Institution for the ...Advancement of Learning/McGill University
more
|
|
|
|
6567963b212eaade2e0edd03
|
2015
|
Canada
|
IDRC
|
2009005509XNB0
|
105509
|
3
|
South & Central Asia, regional
|
South & Central Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0176015
|
0.0389189
|
0
|
0
|
0.0176015
|
0.0389189
|
0
|
0.0176015
|
0
|
0
|
Communicable diseases
|
Communicable diseases Other
|
100
|
ECOHEALTH EMERGING INFECTIOUS ...DISEASES RESEARCH INITIATIVE (ECOEID)
more
|
Ecohealth Emerging Infectious ...Diseases Research Initiative (EcoEID)
more
|
New infectious diseases, mostl...y of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi-country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
International Development Rese...arch Centre
more
|
|
|
|
6567963b212eaade2e0edd04
|
2015
|
Canada
|
IDRC
|
2009005509XOB0
|
105509
|
3
|
South Asia, regional
|
South & Central Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.000977861
|
0.00216694
|
0
|
0
|
0.000977861
|
0.00216694
|
0
|
0.000977861
|
0
|
0
|
Communicable diseases
|
Communicable diseases Other
|
100
|
ECOHEALTH EMERGING INFECTIOUS ...DISEASES RESEARCH INITIATIVE (ECOEID)
more
|
Ecohealth Emerging Infectious ...Diseases Research Initiative (EcoEID)
more
|
New infectious diseases, mostl...y of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi-country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
International Development Rese...arch Centre
more
|
|
|
|
6567963b212eaade2e0edd05
|
2016
|
Canada
|
International Development Rese...arch Centre
more
|
2015008016X7A2
|
108016
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
1.55425E-18
|
0
|
0
|
0
|
1.55425E-18
|
0
|
0
|
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CLINICAL TRIALS OF AN EXPERIME...NTAL EBOLA VACCINE: A CANADIAN RESEARCH RESPONSE
more
|
Clinical Trials of an Experime...ntal Ebola Vaccine: A Canadian Research Response
more
|
This initiative supports phase...s 2 and 3 clinical trials of an experimental Ebola vaccine. The experimental vaccine is based on an attenuated recombinant Vesicular Stomatitis Virus vector (VSV-EBOV). The Public Health Agency of Canada developed the vaccine and licensed it to NewLink Genetics and Merck. Early vaccine trialsDuring the multicentre phase 1 trials, researchers demonstrated the vaccine's safety and its ability to provoke an immune response (immunogenicity). The next trials will determine the expanded safety, protective immune response, and efficacy of the vaccine with at-risk populations in Africa. The trials will allow African teams to strengthen their clinical research capacities. The initiative is supported through a partnership of Foreign Affairs, Trade and Development Canada, the Canadian Institutes of Health Research, IDRC, and the Public Health Agency of Canada.Phases 2 and 3 clinical trialsThe phase 3 clinical trial of the VSV-EBOV vaccine will take place in Guinea, one of the main Ebola-affected countries in West Africa. An international research consortium headed by the Norwegian Institute of Public Health is leading the trials. The World Health Organization is coordinating the consortium. The clinical trial will determine the safety, protective immune response, and efficacy of the vaccine to prevent infection and the spread of the disease. Working with colleagues from Mali and Senegal, Canada will provide support for field monitoring, trial assessment, and developing Guinean clinical research capacities. The Centre hospitalier universitaire Sainte-Justine will host and chair the Data Safety Monitoring Board, an essential validating and transparency function for the vaccine trials. Canada will co-chair the Scientific Advisory Group for the Guinea Ebola vaccine trials.The partnership is discussing support for additional phase 2 clinical trials of the VSV-EBOV vaccine. These would take place in Canada and one at-risk African country not affected by the current epidemic. These trials would be performed in partnership with other donors. This will help create strong evidence of the vaccine's safety and protective immune response in broader populations, including children and HIV-positive people.Results from the project activities will be shared with the international community as part of the global response to the Ebola crisis. The results will inform the approval of the VSV-EBOV vaccine for future use to prevent Ebola transmission.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
International Development Rese...arch Centre
more
|
|
|
|
6567963b212eaade2e0edd06
|
2017
|
Canada
|
Global Affairs Canada
|
20172004970005
|
P000184001
|
1
|
Bangladesh
|
South & Central Asia
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
3.08143E-9
|
0.15176
|
0
|
0
|
3.08143E-9
|
0.15176
|
0
|
3.08143E-9
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
INSTITUTIONAL SUPPORT TO THE I...NTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH-III/SOUTIEN INSTITUTIONNEL AU CENTRE INTERNATIONAL DE RE
more
|
Institutional Support to the I...nternational Centre for Diarrhoeal Disease Research, Bangladesh-III/Soutien institutionnel au Centre international de recherche sur les maladies diarrhéiques–phase III
more
|
This contribution represents C...anada's long-term institutional support to the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), a non-profit international health research, service, and training institution. icddr,b uses these funds, along with other donors' funding, to achieve its mandate.icddr,b's mandate is to provide free, high quality health care for the poor in Bangladesh, including maternal and child health services and treatment for diarrhoeal and other diseases. It also supports research that is designed to generate the data needed to develop policies and practices to address significant health challenges in Bangladesh and other countries.Canada's support to icddr,b contributes to ensuring that icddr,b is providing effective, evidence-based, gender-responsive health care and health education services for the poor. It also ensures that the icddr,b can continue to conduct important health research that translates into policies that can help to improve the health and reduce poverty levels of Bangladeshis. Canada's institutional support is also helping to strengthen the management systems and improve the sustainability of the Centre./ Cette contribution représente le soutien institutionnel à long terme du Canada au Centre international de recherche sur les maladies diarrhéiques du Bangladesh (CIRMD – Bangladesh), un institut international de recherche, de services et de formation dans le secteur de la santé à but non lucratif. Le CIRMD utilise ces fonds, ainsi que ceux octroyés par d'autres donateurs, pour mener à bien son mandat.Le CIRMD a pour mandat d'offrir gratuitement des soins de santé de qualité aux personnes démunies du Bangladesh, y compris des services de santé maternelle et infantile et un traitement des maladies diarrhéiques, entre autres. En outre, il soutient les activités de recherche qui sont conçues pour générer les données probantes nécessaires à l'élaboration de politiques et de pratiques destinées à régler d'importants problèmes de santé au Bangladesh et dans d'autres pays.Le soutien du Canada contribue à faire en sorte que le CIRMD offre aux pauvres une éducation dans le domaine de la santé et des soins de santé efficaces, fondés sur des données probantes et tenant compte des sexospécificités. Il fait aussi en sorte que le CIRMD puisse continuer de réaliser d'importants travaux de recherche en santé qui débouchent sur des politiques pouvant aider à améliorer la santé et réduire le taux de pauvreté au Bangladesh. Le soutien institutionnel du Canada aide aussi à renforcer les systèmes de gestion et à accroître la viabilité du CIRMD.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
47053
|
International Centre for Diarr...hoeal Disease Research, Bangladesh
more
|
International Centre for Diarr...hoeal Disease Research, Bangladesh
more
|
|
|
|
6567963b212eaade2e0edd07
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2014007650XZA3
|
107650
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.00592422
|
0
|
0
|
0
|
0.0296211
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
20
|
CATALYZING OPEN AND COLLABORAT...IVE SCIENCE TO ADDRESS GLOBAL DEVELOPMENT CHALLENGES
more
|
Catalyzing Open and Collaborat...ive Science to Address Global Development Challenges
more
|
Climate change, environmental ...degradation, emerging infectious diseases, inadequate access to clean drinking water, and food insecurity affect all parts of the world. However, their impacts on developing economies are highly disproportionate with developed economies. This project will explore the potential of open and collaborative science to address these development challenges.Sound technology-based solutionsAddressing these challenges requires solutions that are relevant to developing country contexts. They must include the best tools and approaches that are quick to deploy and sustainable over time. As the cost of computer hardware continues to drop and developing-country researchers get increased access to the Internet and mobile phones, each offers the potential for solving these development challenges by opening up the scientific process.What is open science?At the heart of the open science concept is the idea that scientific data, methods, and findings should be freely shared to encourage scientists and the public to collaborate on solving scientific problems. Examples include crowdsourcing to map and monitor deforestation in Brazil to support conservation efforts in the Amazon. The human genome project is another example, where the open sharing of sequence data over the Internet encouraged innovations and spurred major growth in the biotechnology and biomedical industries. Similarly, in Accra, Ghana, carbon monoxide sensors, coupled with mobile phones and global positioning system trackers in taxis, are allowing city officials to generate real-time maps to identify areas with high pollution.The costs and risks of open scienceVery little is known about the added value and costs of opening up the scientific process, particularly with respect to scientific research for development challenges. Open science supporters herald its ability to accelerate the pace of scientific discoveries and make scientific processes more accessible, participatory, and locally relevant. Critics raise the following risks:-privacy; -breakdown of incentive systems for those seeking to commercialize research results; -potential for false conclusions based on unverifiable data sources; or -use (or misuse) of data or findings by the public or commercial entities.Evaluating whether open science can advance development goalsThis research project will support a competitive call for proposals on the issue. The goal is to generate a set of locally relevant research studies that provides evidence on whether open approaches to science contribute to development goals, and if so, under what conditions.The project will also build a community of open science research leaders in developing countries to advocate for evidence-based changes to science policy and practice. The University of Toronto Scarborough (Canada) and the Innovation Hub (Kenya) will coordinate the project.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
23000
|
Local/Regional NGOs
|
I-HUB LIMITED
|
|
|
|
6567963b212eaade2e0edd08
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2014007650XZA2
|
107650
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.00303952
|
0
|
0
|
0
|
0.0151976
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
20
|
CATALYZING OPEN AND COLLABORAT...IVE SCIENCE TO ADDRESS GLOBAL DEVELOPMENT CHALLENGES
more
|
Catalyzing Open and Collaborat...ive Science to Address Global Development Challenges
more
|
Climate change, environmental ...degradation, emerging infectious diseases, inadequate access to clean drinking water, and food insecurity affect all parts of the world. However, their impacts on developing economies are highly disproportionate with developed economies. This project will explore the potential of open and collaborative science to address these development challenges.Sound technology-based solutionsAddressing these challenges requires solutions that are relevant to developing country contexts. They must include the best tools and approaches that are quick to deploy and sustainable over time. As the cost of computer hardware continues to drop and developing-country researchers get increased access to the Internet and mobile phones, each offers the potential for solving these development challenges by opening up the scientific process.What is open science?At the heart of the open science concept is the idea that scientific data, methods, and findings should be freely shared to encourage scientists and the public to collaborate on solving scientific problems. Examples include crowdsourcing to map and monitor deforestation in Brazil to support conservation efforts in the Amazon. The human genome project is another example, where the open sharing of sequence data over the Internet encouraged innovations and spurred major growth in the biotechnology and biomedical industries. Similarly, in Accra, Ghana, carbon monoxide sensors, coupled with mobile phones and global positioning system trackers in taxis, are allowing city officials to generate real-time maps to identify areas with high pollution.The costs and risks of open scienceVery little is known about the added value and costs of opening up the scientific process, particularly with respect to scientific research for development challenges. Open science supporters herald its ability to accelerate the pace of scientific discoveries and make scientific processes more accessible, participatory, and locally relevant. Critics raise the following risks:-privacy; -breakdown of incentive systems for those seeking to commercialize research results; -potential for false conclusions based on unverifiable data sources; or -use (or misuse) of data or findings by the public or commercial entities.Evaluating whether open science can advance development goalsThis research project will support a competitive call for proposals on the issue. The goal is to generate a set of locally relevant research studies that provides evidence on whether open approaches to science contribute to development goals, and if so, under what conditions.The project will also build a community of open science research leaders in developing countries to advocate for evidence-based changes to science policy and practice. The University of Toronto Scarborough (Canada) and the Innovation Hub (Kenya) will coordinate the project.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governing Council of the U...niversity of Toronto
more
|
|
|
|
6567963c212eaade2e0edd09
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2014007650XZA4
|
107650
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.000925136
|
0
|
0
|
0
|
0.00462568
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
20
|
CATALYZING OPEN AND COLLABORAT...IVE SCIENCE TO ADDRESS GLOBAL DEVELOPMENT CHALLENGES
more
|
Catalyzing Open and Collaborat...ive Science to Address Global Development Challenges
more
|
Climate change, environmental ...degradation, emerging infectious diseases, inadequate access to clean drinking water, and food insecurity affect all parts of the world. However, their impacts on developing economies are highly disproportionate with developed economies. This project will explore the potential of open and collaborative science to address these development challenges.Sound technology-based solutionsAddressing these challenges requires solutions that are relevant to developing country contexts. They must include the best tools and approaches that are quick to deploy and sustainable over time. As the cost of computer hardware continues to drop and developing-country researchers get increased access to the Internet and mobile phones, each offers the potential for solving these development challenges by opening up the scientific process.What is open science?At the heart of the open science concept is the idea that scientific data, methods, and findings should be freely shared to encourage scientists and the public to collaborate on solving scientific problems. Examples include crowdsourcing to map and monitor deforestation in Brazil to support conservation efforts in the Amazon. The human genome project is another example, where the open sharing of sequence data over the Internet encouraged innovations and spurred major growth in the biotechnology and biomedical industries. Similarly, in Accra, Ghana, carbon monoxide sensors, coupled with mobile phones and global positioning system trackers in taxis, are allowing city officials to generate real-time maps to identify areas with high pollution.The costs and risks of open scienceVery little is known about the added value and costs of opening up the scientific process, particularly with respect to scientific research for development challenges. Open science supporters herald its ability to accelerate the pace of scientific discoveries and make scientific processes more accessible, participatory, and locally relevant. Critics raise the following risks:-privacy; -breakdown of incentive systems for those seeking to commercialize research results; -potential for false conclusions based on unverifiable data sources; or -use (or misuse) of data or findings by the public or commercial entities.Evaluating whether open science can advance development goalsThis research project will support a competitive call for proposals on the issue. The goal is to generate a set of locally relevant research studies that provides evidence on whether open approaches to science contribute to development goals, and if so, under what conditions.The project will also build a community of open science research leaders in developing countries to advocate for evidence-based changes to science policy and practice. The University of Toronto Scarborough (Canada) and the Innovation Hub (Kenya) will coordinate the project.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governing Council of the U...niversity of Toronto
more
|
|
|
|
6567963c212eaade2e0edd0a
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2014007650XZA1
|
107650
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.000617518
|
0
|
0
|
0
|
0.00308759
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
20
|
CATALYZING OPEN AND COLLABORAT...IVE SCIENCE TO ADDRESS GLOBAL DEVELOPMENT CHALLENGES
more
|
Catalyzing Open and Collaborat...ive Science to Address Global Development Challenges
more
|
Climate change, environmental ...degradation, emerging infectious diseases, inadequate access to clean drinking water, and food insecurity affect all parts of the world. However, their impacts on developing economies are highly disproportionate with developed economies. This project will explore the potential of open and collaborative science to address these development challenges.Sound technology-based solutionsAddressing these challenges requires solutions that are relevant to developing country contexts. They must include the best tools and approaches that are quick to deploy and sustainable over time. As the cost of computer hardware continues to drop and developing-country researchers get increased access to the Internet and mobile phones, each offers the potential for solving these development challenges by opening up the scientific process.What is open science?At the heart of the open science concept is the idea that scientific data, methods, and findings should be freely shared to encourage scientists and the public to collaborate on solving scientific problems. Examples include crowdsourcing to map and monitor deforestation in Brazil to support conservation efforts in the Amazon. The human genome project is another example, where the open sharing of sequence data over the Internet encouraged innovations and spurred major growth in the biotechnology and biomedical industries. Similarly, in Accra, Ghana, carbon monoxide sensors, coupled with mobile phones and global positioning system trackers in taxis, are allowing city officials to generate real-time maps to identify areas with high pollution.The costs and risks of open scienceVery little is known about the added value and costs of opening up the scientific process, particularly with respect to scientific research for development challenges. Open science supporters herald its ability to accelerate the pace of scientific discoveries and make scientific processes more accessible, participatory, and locally relevant. Critics raise the following risks:-privacy; -breakdown of incentive systems for those seeking to commercialize research results; -potential for false conclusions based on unverifiable data sources; or -use (or misuse) of data or findings by the public or commercial entities.Evaluating whether open science can advance development goalsThis research project will support a competitive call for proposals on the issue. The goal is to generate a set of locally relevant research studies that provides evidence on whether open approaches to science contribute to development goals, and if so, under what conditions.The project will also build a community of open science research leaders in developing countries to advocate for evidence-based changes to science policy and practice. The University of Toronto Scarborough (Canada) and the Innovation Hub (Kenya) will coordinate the project.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
23000
|
Local/Regional NGOs
|
I-HUB LIMITED
|
|
|
|
6567963c212eaade2e0edd0b
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2017008517XNA1
|
108517
|
1
|
South & Central Asia, regional
|
South & Central Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0511597
|
0.0200691
|
0
|
0
|
0.0511597
|
0.0200691
|
0
|
0.0511597
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
6567963c212eaade2e0edd0c
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2017008517XNA2
|
108517
|
1
|
South & Central Asia, regional
|
South & Central Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0443314
|
0.0167295
|
0
|
0
|
0.0443314
|
0.0167295
|
0
|
0.0443314
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
11000
|
Donor government
|
Institut national de la recher...che agronomique FR
more
|
|
|
|
6567963d212eaade2e0edd0d
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2013006559X3A1
|
106559
|
3
|
South America, regional
|
South America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0357353
|
0
|
0
|
0
|
0.0357353
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SCALING UP INTERMITTENT RICE I...RRIGATION FOR MALARIA CONTROL ON THE NORTH COAST OF PERU
more
|
Scaling up Intermittent Rice I...rrigation for Malaria Control on the North Coast of Peru
more
|
New research aims to help cont...rol malaria in one watershed in northern Peru. Malaria is widespread in Peru's arid North Coast because of the extensive irrigation required to support rice paddies. Rice growing in the region accounts for 60% of national production and is growing by more than 5% per year. Rice covers 42% of Peru's arable land. The water used for rice farming is a breeding ground for malarial mosquitoes that have grown resistant to pesticides and that now pose serious public health problems in the region. At the same time, climate variability and change are threatening the sources of irrigation water and forcing farmers to seek alternative farming methods. Previous ecohealth research supported by IDRC in the Lambayeque region confirm that intermittent rice irrigation could reduce the number of mosquitoes and malaria outbreaks, conserve water, and increase rice yields by 25%. However, uptake of this approach has been slow and haphazard. The research aims to foster uptake of intermittent irrigation at the watershed level (Valle de Jequetepeque in La Libertad) by exploring ways to: - disseminate knowledge and skills (farmer-to-farmer agricultural extension); - assess and document social, health, environmental, and economic trade-offs as farmers adopt new practices; and - help establish policies and multi-sectoral support programs to promote and guide this approach. The expected outcome is better health, environment, and quality of life for rice farmers and communities of Peru's North Coast.
more
|
|
31181
|
Agricultural education/trainin...g
more
|
|
III.1.a. Agriculture
|
12000
|
Recipient government
|
Ministerio de Salud of the Rep...ublica del Peru
more
|
|
|
|
6567963d212eaade2e0edd0e
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2017008411X3A1
|
108411
|
1
|
South America, regional
|
South America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.3898
|
0.122179
|
0
|
0
|
0.3898
|
0.122179
|
0
|
0.3898
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UNDERSTANDING THE BIOLOGICAL M...ECHANISMS OF ZIKA VIRUS DISEASE
more
|
Understanding the biological m...echanisms of Zika virus disease
more
|
Zika virus is an emerging mosq...uito-transmitted human pathogen which has affected over 50 countries to date. More than 2 million infections and 4,000 suspected cases of Zika virus-related birth defects have been recorded in Brazil. Unfortunately, there are no antivirals or vaccines currently available against the virus.Zika virus is a unique pathogen with a complex transmission and pathogenic profile. Zika Virus can be spread through mosquitos as well as via sexual and vertical transmission. Zika Virus also causes a wide spectrum of disease ranging from symptom-free infections to mild, self-limiting symptoms, or sometimes, severe infections requiring hospitalization. Additionally, Zika infections in pregnant women has been linked to microcephaly and other brain abnormalities in developing fetuses and newborn infants. Zika-affected areas in Brazil have shown an unprecedented rise in birth defects. The complexity and severity of this virus underscores the need for greater research to understand the molecular mechanisms which allow Zika virus to infect, persist and spread through infected human cases. This project will use advanced biomolecular, genomics and proteomics techniques to explain the molecular mechanisms by which Zika virus infects and persists in the human body, how it affects the human reproductive and central nervous system, and how the risk of fetal abnormalities can be better predicted in infected pregnant mothers. Through this research, this project will provide critical information about how Zika virus infects and persists in the human body, how it can be spread through sexual transmission, and how it affects pregnant women and their infants. By doing so, the project may identify new opportunities for developing therapies to prevent severe illness in mothers and their infants, and to reduce sexual transmission.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
23000
|
Local/Regional NGOs
|
Fundaçao Oswaldo Cruz- FIOCRU...Z
more
|
|
|
|
6567963d212eaade2e0edd0f
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2017008517X7A1
|
108517
|
1
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0511597
|
0.0200691
|
0
|
0
|
0.0511597
|
0.0200691
|
0
|
0.0511597
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
6567963d212eaade2e0edd10
|
2017
|
Canada
|
International Development Rese...arch Centre
more
|
2017008517X7A2
|
108517
|
1
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0443314
|
0.0167295
|
0
|
0
|
0.0443314
|
0.0167295
|
0
|
0.0443314
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
11000
|
Donor government
|
Institut national de la recher...che agronomique FR
more
|
|
|
|
6567963d212eaade2e0edd11
|
2020
|
Canada
|
Global Affairs Canada
|
20182007820001
|
P001405001
|
3
|
Bangladesh
|
South & Central Asia
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
0.104384
|
0
|
0
|
0
|
0.104384
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ICDDR,B - INSTITUTIONAL SUPPOR...T 2018-2022/ICDDR,B - APPUI INSTITUTIONNEL 2018-2022
more
|
icddr,b - Institutional Suppor...t 2018-2022/icddr,b - Appui institutionnel 2018-2022
more
|
This grant represents Canada's... long-term institutional support to icddr,b, formerly known as the International Centre for Diarrhoeal Disease Research, Bangladesh. icddr,b uses these funds, along with other donors' funding to achieve its mandate. icddr,b's mandate is to find low-cost innovative solutions to public health problems facing low- and middle-income countries through scientific research. icddr,b's research and health services contribute to the well-being of women and girls in the area of disease prevention and control (including cholera vaccines administered to Rohingya refugees), sexual and reproductive health and rights, prevention and treatment of malnutrition, prevention of child marriage, and the first population-based research on gender-based violence in Bangladesh. As part of icddr,b's 'Core Donor Group' (Canada, UK, Sweden), Canada's funding is supporting the delivery of free health care, especially for women and children, and strengthening icddr,b's operations through investment in research technologies, human resources development, and initiatives to improve icddr,b's effectiveness, efficiency, and long-term viability. / Cette subvention constitue l'appui institutionnel à long terme du Canada à icddr,b - qui était connu sous le nom Centre international de recherche sur les maladies diarrhéiques, Bangladesh, en anglais : International Centre for Disease Research, Bangladesh. icddr,b utilise ces fonds, ainsi que ceux d'autres donateurs, pour la réalisation de son mandat. Le mandat de icddr,b consiste à trouver des solutions novatrices peu coûteuses aux problèmes de santé publique auxquels sont confrontés les pays à revenu faible ou intermédiaire grâce à la recherche scientifique. La recherche et les services de santé de icddr,b contribuent au bien-être des femmes et des filles dans le domaine de la prévention et du contrôle des maladies (y compris les vaccins cholériques administrés aux réfugiés Rohingya), la santé et les droits sexuels et reproductifs, la prévention de la malnutrition, le mariage des enfants et la première recherche en population sur la violence sexiste au Bangladesh. Faisant partie du groupe de donateurs de base de icddr,b (Canada, Royaume-Uni, Suède), le financement du Canada appuie la prestation gratuite de soins de santé, en particulier pour les femmes et les enfants, et renforce les activités d'icddr,b en investissant dans les technologies de recherche, le développement des ressources humaines, et les initiatives visant à améliorer l'efficacité, l'efficience et la viabilité à long terme d'icddr,b.
more
|
|
13081
|
Personnel development for popu...lation and reproductive health
more
|
3,2
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
47053
|
International Centre for Diarr...hoeal Disease Research, Bangladesh
more
|
icddr,b
|
|
|
|
6567963d212eaade2e0edd12
|
2018
|
Canada
|
Global Affairs Canada
|
20182007820002
|
P001405001
|
3
|
Bangladesh
|
South & Central Asia
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
0.0601805
|
0
|
0
|
0
|
0.0601805
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ICDDR,B - INSTITUTIONAL SUPPOR...T 2018-2022/ICDDR,B - APPUI INSTITUTIONNEL 2018-2022
more
|
icddr,b - Institutional Suppor...t 2018-2022/icddr,b - Appui institutionnel 2018-2022
more
|
icddr,b - Institutional Suppor...t 2018-2022 / icddr,b - Appui institutionnel 2018-2022
more
|
|
13081
|
Personnel development for popu...lation and reproductive health
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
47053
|
International Centre for Diarr...hoeal Disease Research, Bangladesh
more
|
icddr,b
|
|
|
|
6567963d212eaade2e0edd13
|
2018
|
Canada
|
Global Affairs Canada
|
20182007820003
|
P001405001
|
1
|
Bangladesh
|
South & Central Asia
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
1.54309
|
0
|
0
|
0
|
1.54309
|
0
|
0
|
1.54309
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ICDDR,B - INSTITUTIONAL SUPPOR...T 2018-2022/ICDDR,B - APPUI INSTITUTIONNEL 2018-2022
more
|
icddr,b - Institutional Suppor...t 2018-2022/icddr,b - Appui institutionnel 2018-2022
more
|
icddr,b - Institutional Suppor...t 2018-2022 / icddr,b - Appui institutionnel 2018-2022
more
|
|
13081
|
Personnel development for popu...lation and reproductive health
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
47053
|
International Centre for Diarr...hoeal Disease Research, Bangladesh
more
|
icddr,b
|
|
|
|
65679641212eaade2e0edd14
|
2018
|
Canada
|
International Development Rese...arch Centre
more
|
20140076500001
|
107650
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0
|
0.00305338
|
0
|
0
|
0
|
0.0152669
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
20
|
CATALYZING OPEN AND COLLABORAT...IVE SCIENCE TO ADDRESS GLOBAL DEVELOPMENT CHALLENGES
more
|
Catalyzing Open and Collaborat...ive Science to Address Global Development Challenges
more
|
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
23000
|
Developing country-based NGO
|
I-HUB LIMITED
|
|
|
|
65679641212eaade2e0edd15
|
2018
|
Canada
|
International Development Rese...arch Centre
more
|
20140076500002
|
107650
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0
|
0.001655736
|
0
|
0
|
0
|
0.00827868
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
20
|
CATALYZING OPEN AND COLLABORAT...IVE SCIENCE TO ADDRESS GLOBAL DEVELOPMENT CHALLENGES
more
|
Catalyzing Open and Collaborat...ive Science to Address Global Development Challenges
more
|
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governing Council of the U...niversity of Toronto
more
|
|
|
|
65679642212eaade2e0edd16
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20160084040001
|
108404
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.003795
|
0
|
0
|
0
|
0.003795
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EPITOPE FOCUSED IMMUNOGENS AND... RECOMBINANT ANTIBODY THERAPEUTICS FOR THE CONTROL OF TROPICAL DISEASES
more
|
Epitope focused immunogens and... recombinant antibody therapeutics for the control of tropical diseases
more
|
Tropical diseases in humans an...d livestock can cause death and remain a huge economic and social burden in developing countries. Currently, 3.6 billion people are at risk of dengue infection. Endemic in 100 countries, with an estimated 390 million annual infections and approximately 500,000 hospitalizations yearly, dengue fever is a worldwide challenge for public health officials and policymakers. East Coast fever is a tick-borne disease affecting cattle, caused by the protozoan parasite Theileria parva. With a 3–4 week incubation period and 100% mortality rate in exotic cattle, it has a devastating economic impact on pastoralists and smallholder farmers in Africa. Combining cutting-edge immunology and protein engineering methods, this collaborative research project aims to develop affordable antibody-based therapies for dengue patients and improved vaccines for the control of dengue fever and East Coast fever in both humans and animals. The core technologies that will be employed reduce the use of animals in research and are easy and affordable to implement, which make these approaches particularly appealing to research groups based in low- and middle-income countries. In Canada, the project is led by the University of Toronto, in collaboration with Tel Aviv University (Israel), the International Livestock Research Institute (Kenya), the SciGenom Labs (India), and the Albert Einstein College of Medicine (USA). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, a partnership between IDRC, the Canadian Institutes for Health Research, the Israel Science Foundation, and the Azrieli Foundation. This seven-year, CA$35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. Projects include a plan for integrating researchers from low- and middle-income countries to establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governing Council of the U...niversity of Toronto
more
|
|
|
|
65679642212eaade2e0edd17
|
2018
|
Canada
|
International Development Rese...arch Centre
more
|
20160084060001
|
108406
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.120947
|
0
|
0
|
0
|
0.120947
|
0
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
IMPROVING MICROPHAGE INNATE IM...MUNITY BY MODULATING PROTEIN TYROSINE PHOSPHATASES: THE COMPLETE MOUSE AND HUMAN PTPOMES
more
|
Improving microphage innate im...munity by modulating protein tyrosine phosphatases: The complete mouse and human PTPomes
more
|
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Royal Institution for the ...Advancement of Learning/McGill University
more
|
|
|
|
65679642212eaade2e0edd18
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20160084070001
|
108407
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.008403
|
0
|
0
|
0
|
0.008403
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MITOCHONDRIAL CONTRIBUTION TO ...INNATE IMMUNE PATHWAYS
more
|
Mitochondrial contribution to ...innate immune pathways
more
|
The ability of cells in the bo...dy to recognize bacteria and viruses is critical to survival. Depending on the type of infection, the cell will activate different pathways that generally lead to two distinct responses, first, the cell will secrete proteins called cytokines that alert neighbouring cells to the infection, particularly cells of the immune system. Second, a series of events are triggered to shut down the replication of the pathogen inside the cell. This direct cellular response to infection is called innate immunity. Over the past few years, researchers have identified a critical role for an intracellular organelle, called mitochondria, in the propagation of these signals. Mitochondria are well known as the energy powerhouse of the cell, however, they can also act as a platform to assemble anti-viral and anti-inflammatory signalling. In addition, mitochondria still retain bacterial signatures, including their own unmethylated DNA, as well as the machinery to translate proteins. It was recently shown that this mitochondrial DNA is released into the cell cytoplasm under certain stress conditions. When this happens, the cellular antiviral responses are initiated, as if the cell was infected with bacteria. In this way, mitochondria play a central role as both a signalling platform to launch the protective response to infection, and as a direct activator of this response when their own DNA is released. This project aims to investigate the role of mitochondria in innate immune responses and to develop a detailed understanding of how mitochondria control innate immune signalling pathways. The project is led in Canada by the Montreal Neurological Institute – McGill University in collaboration with the Weizmann Institute (Israel), Universidad Andres Bello (Chile), and the National Institute of Biological Sciences (China). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, which is a partnership between Canada's International Development Research Centre, the Canadian Institutes for Health Research, the Israel Science Foundation and the Azrieli Foundation. This seven-year, $35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. All projects include a plan for integrating researchers from low- and middle-income countries that will establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Royal Institution for the ...Advancement of Learning/McGill University
more
|
|
|
|
65679642212eaade2e0edd19
|
2018
|
Canada
|
International Development Rese...arch Centre
more
|
20170087670002
|
108767
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.578659
|
0
|
0
|
0
|
0.578659
|
0
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SCOPING STUDY FOR A ONE-HEALTH... RESPONSE TO KNOWLEDGE GAPS IN ANTIMICROBIAL RESISTANCE RESEARCH
more
|
Scoping study for a one-health... response to knowledge gaps in antimicrobial resistance research
more
|
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
International Bank for Reconst...ruction and Development
more
|
|
|
|
65679642212eaade2e0edd1a
|
2018
|
Canada
|
International Development Rese...arch Centre
more
|
20170087670001
|
108767
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.578659
|
0
|
0
|
0
|
0.578659
|
0
|
0
|
0.578659
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SCOPING STUDY FOR A ONE-HEALTH... RESPONSE TO KNOWLEDGE GAPS IN ANTIMICROBIAL RESISTANCE RESEARCH
more
|
Scoping study for a one-health... response to knowledge gaps in antimicrobial resistance research
more
|
The spread of antimicrobial re...sistance (AMR) has been dramatically accelerated by overuse and misuse of antimicrobials. As a result, antimicrobial drugs are rapidly losing their effectiveness. Many of the great public health achievements of the past century are at risk, including the reduction in mortality from infectious diseases, increased access to health services, and availability of safe, effective, and affordable medicines. A recent World Bank report finds that drug-resistant infections have the potential to cause economic damage similar to, and likely worse than, that inflicted by the 2008 financial crisis. The worst impacts are projected to be on the poorest countries and people. The objective of the project, implemented in partnership with the International Bank for Reconstruction and Development (a component of the World Bank Group), is to develop an AMR research agenda for low and middle-income countries. This will be achieved by conducting a comprehensive literature review of interdisciplinary and intervention-focused AMR research related to human health, agriculture, water and sanitation, environment, trade, food security, economic growth, and poverty. The study will include an assessment of current knowledge gaps, as well as existing capacities and ongoing efforts, with a particular focus on the Global South. The project will also identify and prioritize the most promising research areas for further advancement of the AMR containment agenda.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
International Bank for Reconst...ruction and Development
more
|
|
|
|
65679642212eaade2e0edd1b
|
2018
|
Canada
|
Miscellaneous
|
2018899914a
|
156485-1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0115346
|
0
|
0
|
0
|
0.0115346
|
0
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DIGHR WORKSHOP ON ARTIFICIAL I...NTELLIGENCE APPROACHES FOR WATER SAFETY AND PUBLIC HEALTH PROTECTION
more
|
DIGHR Workshop on Artificial I...ntelligence Approaches for Water Safety and Public Health Protection
more
|
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
York University (Toronto, Onta...rio)
more
|
|
|
|
65679642212eaade2e0edd1c
|
2018
|
Canada
|
Miscellaneous
|
2018899914b
|
156485-1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0115346
|
0
|
0
|
0
|
0.0115346
|
0
|
0
|
0.0115346
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DIGHR WORKSHOP ON ARTIFICIAL I...NTELLIGENCE APPROACHES FOR WATER SAFETY AND PUBLIC HEALTH PROTECTION
more
|
DIGHR Workshop on Artificial I...ntelligence Approaches for Water Safety and Public Health Protection
more
|
Diarrheal diseases were respon...sible for more than 1.3 million deaths, including 400,000 among children less than five years of age, globally in 2015. This burden is primarily borne by the marginalized poor in the global South-in neglected rural areas, in urban slums, and in refugee and internally displaced persons (IDP) camps. Other emerging and re-emerging waterborne threats such as hepatitis E and cholera likewise present the threat of potentially catastrophic outbreaks for these populations. In these contexts, safe, treated water that has been chlorinated is essential for protecting public health and preventing potentially catastrophic outbreaks. Water quality-chlorine in particular-is therefore an important factor in understanding the levels of waterborne diseases affecting populations around the world. Artificial intelligence (AI) approaches could help us to better understand the relationship between water quality and waterborne diseases among different populations in the global south, including in urban slums and in refugee/IDP camps. More importantly, AI approaches could potentially be used to develop tools that help us to predict when waterborne diseases outbreaks might occur, simply by looking at widely available water quality data. Predictive tools like this could help public health practitioners globally develop early warning systems for waterborne disease outbreaks such that preventative measures can be taken to limit their extent or prevent them altogether.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
York University (Toronto, Onta...rio)
more
|
|
|
|
65679642212eaade2e0edd1d
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170002
|
108517
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.009991
|
0.010483
|
0
|
0
|
0.009991
|
0.010483
|
0
|
0.009991
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
Institut national de recherche... pour l'agriculture, l'alimentation et l'environnement
more
|
|
|
|
65679642212eaade2e0edd1e
|
2018
|
Canada
|
Miscellaneous
|
2018899956a
|
158407-1
|
3
|
India
|
South & Central Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.00974602
|
0
|
0
|
0
|
0.00974602
|
0
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PLANNING TO EXPLORE THE SOCIAL... DETERMINANTS OF MULTIDRUG-RESISTANT TUBERCULOSIS IN SIKKIM, INDIA
more
|
Planning to explore the social... determinants of multidrug-resistant tuberculosis in Sikkim, India
more
|
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Memorial University of Newfoun...dland
more
|
|
|
|
65679643212eaade2e0edd1f
|
2018
|
Canada
|
Miscellaneous
|
2018899956b
|
158407-1
|
3
|
India
|
South & Central Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0153152
|
0
|
0
|
0
|
0.0153152
|
0
|
0
|
0.0153152
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PLANNING TO EXPLORE THE SOCIAL... DETERMINANTS OF MULTIDRUG-RESISTANT TUBERCULOSIS IN SIKKIM, INDIA
more
|
Planning to explore the social... determinants of multidrug-resistant tuberculosis in Sikkim, India
more
|
Tuberculosis (TB) is one of th...e top 10 causes of death worldwide. In India, there are a staggering 1.7 million people with TB. Whereas the national tuberculosis programs have shown some success in early detection and treatment of TB, multidrug-resistant -TB does not respond to the common treatment of TB. The way to end TB is to prevent it from happening in the first place, addressing the root causes - the social determinants of TB. The root causes are poverty, education, housing, food security, employment, and working conditions. Whereas we know plenty about the social determinants of TB, there is little known about the social determinants of multidrug-resistant TB. The Sikkim state of India has one of the lowest rates of TB in the country, but the highest rates of multidrug-resistant -TB. We seek to plan a consultative gathering in the state of Sikkim located in the North-Eastern part of India to design a collaborative project on understanding the root causes of multidrug-resistant TB. In this planning stage, we will conduct a literature review, visit stakeholders in Sikkim, and design a project grant in collaboration with local partners.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Memorial University of Newfoun...dland
more
|
|
|
